Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eckert & Ziegler SECHIX:EUZD 98 3-Year EBITDA Growth Rate is 17.40% as of Jun. 2026, which is 87% above its 10-year median of 9.30. GuruFocus rates CHIX:EUZD with a GF Score™ of 98/100 and a GF Value™ of €15.91 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 691 Medical Devices & Instruments companies, Eckert & Ziegler SE ranks better than 62.81% on this metric.
During the past 12 months, Eckert & Ziegler SE's average EBITDA Per Share Growth Rate was 11.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 14.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Eckert & Ziegler SE was 65.80% per year. The lowest was -13.40% per year. And the median was 9.30% per year.
Eckert & Ziegler SE (CHIX:EUZd) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Eckert & Ziegler SE 3-Year EBITDA Growth Rate Related Terms
CHIX:EUZD vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's 3-Year EBITDA Growth Rate falls into.
Eckert & Ziegler SE 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.40% mean?
Eckert & Ziegler SE (CHIX:EUZD) has a 3-Year EBITDA Growth Rate of 17.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Eckert & Ziegler SE and its competitors. This is 87% above median its historical median of 9.30. According to the industry distribution chart, Eckert & Ziegler SE ranks #257 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 37.2%.
Is Eckert & Ziegler SE's 3-Year EBITDA Growth Rate too high?
Eckert & Ziegler SE's current 3-Year EBITDA Growth Rate of 17.40% is 87% above median its 10-year median of 9.30. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Eckert & Ziegler SE's value of 17.40% is 126% above this industry median. Based on the distribution chart, Eckert & Ziegler SE ranks #257 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #257 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Eckert & Ziegler SE in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.70. Eckert & Ziegler SE's value of 17.40% is 126% above this benchmark. While the company's 10-year median is 9.30 vs. the industry median of 7.70, Eckert & Ziegler SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eckert & Ziegler SE's current 3-Year EBITDA Growth Rate of 17.40% is 126% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current 3-Year EBITDA Growth Rate is 17.40%, which is 87% above median its own 10-year median of 9.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (CHIX:EUZD) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.91, compared to a current price of €13.36 — trading 16% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.40%, which is 87% above median its 10-year median of 9.30 and 126% above the Medical Devices & Instruments industry median of 7.70. Eckert & Ziegler SE's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Eckert & Ziegler SE (CHIX:EUZD), the current 3-Year EBITDA Growth Rate is 17.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €13.36 is trading 16% below its estimated GF Value™ of €15.91.
GuruFocus considers Eckert & Ziegler SE to be Modestly Undervalued.
Key valuation signals for CHIX:EUZD:
3-Year EBITDA Growth Rate: 17.40% (87% above median its 10-year median of 9.30)
GF Value™: €15.91 vs. price of €13.36 (16% below fair value)
Industry Position: 126% above the Medical Devices & Instruments median (#257 of 691)
No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score
Get the complete analysis for CHIX:EUZD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EUZD has been successfully added to your 
